This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/kegg-drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/pubchem-substance/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/national-drug-code-directory/
n8http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n24http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/chebi/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/pharmgkb/
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n18http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00561/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00561
rdf:type
n3:Drug
n3:description
A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
n3:dosage
n16:271B47D5-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Singh P, Dimitriou V, Mahajan RP, Crossley AW: Double-blind comparison between doxapram and pethidine in the treatment of postanaesthetic shivering. Br J Anaesth. 1993 Nov;71(5):685-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8251281 # Yost CS: A new look at the respiratory stimulant doxapram. CNS Drug Rev. 2006 Fall-Winter;12(3-4):236-49. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17227289
n3:group
approved
n3:indication
For use as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease.
n3:manufacturer
n5:271B47D2-363D-11E5-9242-09173F13E4C5 n5:271B47D0-363D-11E5-9242-09173F13E4C5 n5:271B47D1-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00561 n19:DB00561
dcterms:title
Doxapram
adms:identifier
n10:Doxapram n13:PA164784026 n17:46506829 n20:3156 n21:D01872 n22:55390-035-01 n23:DB00561 n24:681848 n25:3044
n3:mechanismOfAction
Doxapram produces respiratory stimulation mediated through the peripheral carotid chemoreceptors. It is thought to stimulate the carotid body by inhibiting certain potassium channels.
n3:packager
n5:271B47CD-363D-11E5-9242-09173F13E4C5 n5:271B47CE-363D-11E5-9242-09173F13E4C5 n5:271B47CC-363D-11E5-9242-09173F13E4C5 n5:271B47CF-363D-11E5-9242-09173F13E4C5
n3:synonym
Doxapram Doxapramum 1-Ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone (+-)-Doxapram
n3:toxicity
Intravenous LD<sub>50</sub> values in the mouse and rat were approximately 75 mg/kg and in the cat and dog were 40 to 80 mg/kg. Symptoms of overdosage are extensions of the pharmacologic effects of the drug. Excessive pressor effect, tachycardia, skeletal muscle hyperactivity, and enhanced deep tendon reflexes may be early signs of overdosage.
n3:salt
n3:synthesisReference
Lunsford, C.D. and Cale, A.D. Jr.; U S . Patent 3,192,230; June 29, 1965; assigned to A.H. Robins Company, Inc.
foaf:page
n12:doxapram.html n18:doxapram.htm
n3:IUPAC-Name
n6:271B47DA-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B47E0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B47DF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B47DC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B47DD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B47DE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B47EF-363D-11E5-9242-09173F13E4C5 n6:271B47D8-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B47D9-363D-11E5-9242-09173F13E4C5 n6:271B47F1-363D-11E5-9242-09173F13E4C5 n6:271B47D6-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B47D7-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:R07AB01
n3:H-Bond-Acceptor-Count
n6:271B47E6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B47E7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B47E1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B47E2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B47E4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B47E3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B47E5-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
309-29-5
n3:containedIn
n4:271B47D3-363D-11E5-9242-09173F13E4C5 n4:271B47D4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B47EB-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B47ED-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B47EE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B47F0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B47EA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B47E9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B47EC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B47DB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B47E8-363D-11E5-9242-09173F13E4C5